Key facts
- This page summarizes John Glenn's Form 4 filing for IRADIMED CORP (IRMD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Dec 2022, 09:43.
John Glenn - 07 Dec 2022 Form 4 Insider Report for IRADIMED CORP (IRMD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IRMD
- Reported as of
- 07 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2022, 09:43:58 UTC
- Prior SEC filing
- 08 Jul 2022
- Next SEC filing
- 16 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Glenn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Glenn filed Form 4 for IRADIMED CORP (IRMD) on 09 Dec 2022.
Change
- Previous filing in this sequence was filed on 08 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRMD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +10,504
- Change %
- +45%
- Price
- $0.000000
- Shares after
- 33,687
- Date
- 07 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,504
- Exercise price
- Footnotes
- F1, F2
IRMD
transaction
Derivative
Performance-based Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +10,504
- Change %
- Price
- $0.000000
- Shares after
- 10,504
- Date
- 07 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,504
- Exercise price
- Footnotes
- F1, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock.
Footnote F2
The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in full on the third anniversary of the grant date, December 7, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
Footnote F3
The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2014 Equity Incentive Plan. Vesting of these PRSUs depends on the reporting person's achievement of a specified relative ranking of total stockholder return over a three-year period from December 8, 2022 through December 7, 2025.
Footnote F4
If the relative measure at December 7, 2025 and for the three-year period then ended is: (i) less than or equal to 80% of the peer group, no vesting would occur, (ii) between 80% and 100% of the peer group, the number of shares vesting would be pro-rata against the nominal granted shares, (iii) equal to 100% of the peer group, the number of shares vesting would be the nominal granted shares, (iv) between 100% and 120% of the peer group, the number of shares vesting would be pro-rata against an additional tranche of the nominal granted shares plus the nominal granted shares, and (v) if 120% or greater of the peer group, the number of shares vesting would be double the nominal granted shares.
Footnote F5
Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of PRSUs that have vested.